KC Specialty Therapeutics' Acquisition

KC Specialty Therapeutics was acquired by Kagen Pharmaceuticals on December 13, 2017.

KC Specialty Therapeutics is focused on the development of Orphan drugs for indications which affect less than 200,000 people per year.…

Articles about KC Specialty Therapeutics' Acquisition: